Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Dasatinib
Procedure: Surgical Resection

First Posted Date: 2010-03-25

Last Posted Date: 2016-09-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01092728

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Drug: Sirolimus
Drug: Everolimus
Drug: Vorinostat
Drug: Temsirolimus

First Posted Date: 2010-03-16

Last Posted Date: 2025-01-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 249

Registration Number: NCT01087554

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lapatinib With Sirolimus or Metformin

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Lapatinib
Drug: Metformin
Drug: Sirolimus

First Posted Date: 2010-03-16

Last Posted Date: 2015-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT01087983

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Imatinib Mesylate
Drug: Docetaxel

First Posted Date: 2010-03-10

Last Posted Date: 2012-01-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01083589

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Alemtuzumab
Drug: Rituximab

First Posted Date: 2010-03-09

Last Posted Date: 2012-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT01082939

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and High-Dose Melphalan

Phase 1

Completed

Conditions: Myeloma
Stem Cell Transplantation

Interventions: Drug: Lenalidomide
Drug: Melphalan
Procedure: Stem Cell Infusion

First Posted Date: 2010-03-03

Last Posted Date: 2016-06-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT01079936

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Neoadjuvant Hormonal Therapy
Drug: Docetaxel

First Posted Date: 2010-02-26

Last Posted Date: 2016-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01076335

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

Phase 2

Completed

Conditions: Lymphoma

Interventions: Radiation: TSEBT

First Posted Date: 2010-02-23

Last Posted Date: 2015-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01073267

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Letrozole
Drug: RAD001 (Everolimus)

First Posted Date: 2010-02-12

Last Posted Date: 2025-05-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT01068249

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Morristown Memorial Hospital, Women's Cancer Center, Morristown, New Jersey, United States

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Phase 2

Completed

Conditions: Brain Cancer
Glioblastoma

Interventions: Drug: Standard Dose Bevacizumab
Drug: Low Dose Bevacizumab
Drug: Lomustine

First Posted Date: 2010-02-11

Last Posted Date: 2020-03-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 83

Registration Number: NCT01067469

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy